Manitoba, CA —18 July 2025— With increasing global demand for advanced weight loss solutions, Canadian consumers now have a new way to access the recently approved obesity treatment Zepbound. Online pharmacy DutyFreeMeds.com is among the first platforms to make Zepbound available for Canadian patients, offering affordability and convenience amid skyrocketing interest in GLP-1 drugs.
Zepbound (tirzepatide), a weight loss injection developed by Eli Lilly, was recently authorized for use in Canada following its success in the U.S. Now hailed as one of the most promising treatments for obesity, the drug targets both GLP-1 and GIP receptors to suppress appetite and enhance weight loss — and has been shown to help patients lose up to 22.5% of body weight in clinical trials.
 | “We’re proud to make Zepbound accessible to Canadians seeking medically-backed weight loss solutions at prices that won’t break the bank,” said Hank Popeil, a representative from DutyFreeMeds.com. “With rising demand and limited access, our platform bridges a critical gap.” |
While Zepbound’s list price in the U.S. remains a barrier for many patients (reportedly over $1,000/month without insurance), we provide a more affordable option for Canadians and US patients alike, often with no prescription markup and transparent sourcing from licensed international pharmacies.
About Duty Free Meds
Duty Free Meds is a trusted prescription fulfillment service based in Manitoba, Canada, dedicated to helping U.S. patients access affordable, high-quality medications. By partnering with licensed pharmacies and certified healthcare professionals, Duty Free Meds ensures all products meet Health Canada standards. With a strong focus on reliability, safety, and cost savings, the company has helped thousands of Americans reduce their out-of-pocket prescription costs through convenient, secure online ordering.
